Molecular biologist whose 1993 discovery that a single daf-2 gene mutation doubles the lifespan of the worm C. elegans reshaped the modern biology of aging.
Facts
- Born
- February 21, 1954
- Field
- Genetics of aging
- Known for
- Doubling the lifespan of C. elegans
- Role
- VP aging research, Calico
- Affiliation
- Emerita professor, UCSF
Background
Cynthia Kenyon is an American molecular biologist and biogerontologist whose work established that aging is controlled by specific genes and can be dramatically slowed. In 1993 she and her colleagues reported that a single mutation in a gene called daf-2 could double the lifespan of the roundworm Caenorhabditis elegans, a finding that helped overturn the long-held assumption that aging is simply passive wear and tear. The discovery is widely regarded as a turning point in the modern biology of aging. Kenyon earned a bachelor's degree in chemistry from the University of Georgia and a PhD from MIT, then joined the laboratory of Sydney Brenner in Cambridge, England, where C. elegans had been developed as a model organism. She established her own laboratory at the University of California, San Francisco in 1986.
The daf-2 discovery
At the time Kenyon began her aging experiments, most biologists doubted that aging was under specific genetic control. Working with C. elegans, her laboratory found that reducing the activity of the single gene daf-2 roughly doubled how long the animals lived, and the long-lived worms remained youthful and active rather than frail. daf-2 encodes a receptor for insulin-like and IGF-1-like hormones, and Kenyon's group showed that its effects require a second gene, daf-16, which switches on protective and repair programs when insulin signaling is low. This nutrient-sensing pathway is one of the mechanisms later catalogued among the hallmarks of agingArticleHallmarks of AgingA shared framework that organizes aging into interconnected biological processes, giving longevity research a common map of what to measure and target.Read entry →. The finding was striking because the same hormonal pathway exists, in modified form, in flies, mice, and humans, suggesting that longevity is regulated by an ancient genetic program that can be tuned by adjusting a small number of molecular switches.
Influence on the field
Kenyon's discovery, with related findings from other laboratories, launched the modern molecular study of aging. Genetic variants in FOXO3, the human counterpart of daf-16, have since been repeatedly associated with exceptional human longevity, including in centenarians. The pathway she illuminated overlaps with the targets of interventions such as rapamycin, which acts on the related mTORTermmTORA cellular signaling hub that senses nutrients and growth signals and controls the balance between growth and maintenance.In glossary → network, and metformin. Her results reframed a broader debate: if lifespan is plastic and genetically tunable, then aging itself, rather than any single disease, becomes a legitimate target for medicine. She co-founded Elixir Pharmaceuticals in the early 2000s to pursue drugs based on longevity genes.
Calico
In 2014 Kenyon joined CalicoCompanyCalicoAlphabet-backed research company founded in 2013 and led by Arthur Levinson that studies the biology of aging and lifespan, known for its secrecy and AbbVie partnership.Company →, the California Life Company, an Alphabet-funded venture created to study the biology of aging and translate it into therapies. As vice president of aging research she has helped guide a program that combines basic research on model organisms with drug discovery. Her move from academia to a well-financed private laboratory reflected a broader shift in which aging science attracted large commercial investment. Kenyon is a member of the National Academy of Sciences and the American Academy of Arts and Sciences and a fellow of the Royal Society, and her 1993 paper remains one of the most cited in the field.